Advertisement
Australia markets closed
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    95,535.22
    +5,841.98 (+6.51%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     
  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

Interim report Q1, 2024: Strong growth in APAC and solid margins

GOTHENBURG, Sweden, April 18, 2024 /PRNewswire/ --

First quarter 

  • Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.

  • Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.

  • Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics.

  • Gross margin increased to 57.1% (56.8).

  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6).

  • Operating cash flow increased to SEK 198 million (160).

  • Net income was SEK 115 (99) million, resulting in earnings per share of SEK 0.85 (0.74).

  • The product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.

VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

ADVERTISEMENT

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 18-04-2024 08:00 CET.

Contact: 
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q1--2024--strong-growth-in-apac-and-solid-margins,c3963367

The following files are available for download:

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/interim-report-q1-2024-strong-growth-in-apac-and-solid-margins-302120652.html

SOURCE Vitrolife AB (publ)